Siglec-2/CD22 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 75.2 kDa and the accession number is P20273-1.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
100 μg | 在庫あり | ¥ 88,500 |
200 μg | 約5 days | ¥ 151,500 |
500 μg | 約5 days | ¥ 307,500 |
生物学的情報 | Testing in progress |
説明 | Siglec-2/CD22 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 75.2 kDa and the accession number is P20273-1. |
Species | Human |
Expression Host | HEK293 Cells |
Tag | Tag Free |
Accession Number | P20273-1 |
別名 | CD22 molecule, SIGLEC2, SIGLEC-2 |
Construction | Human CD22 (NP_001762.2) (Met1-Arg687) |
Protein Purity |
> 95 % as determined by SDS-PAGE.
|
分子量 | 75.2 kDa (predicted) |
Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
Stability & Storage |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. |
Research Background | CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
Siglec-2/CD22 Protein, Human, Recombinant CD22 molecule SIGLEC 2 SIGLEC2 SIGLEC-2 recombinant recombinant-proteins proteins protein